米乐m6
About Henlius
米乐m6:Company Profile
米乐m6:Corporate Culture
Honor
Board of Directors
Management Team
Advisory Committee
Product
米乐m6:Marketed Products
米乐m6:Products in R&D
米乐m6:Clinical Trial
米乐m6:Science & Technology
米乐m6:R&D Result
米乐m6:Innovation Centre
米乐m6:Technology Platform
Quality Management
Manufacturing
Collaborations
Investor Relations
Information Disclosure
Corporate Governance
米乐m6:Financial Reports
Stock Info
IR Calendar
米乐m6:Investor Presentation
米乐m6:Analyst Coverage
米乐m6:Contact Information
Media
Press Release
米乐m6:Multi-media
Media Reports
米乐m6:Media Enquiry
Careers
Talent Philosophy
米乐m6:Staff Life
Training and Development
米乐m6:Contact Us
米乐m6:Contact Information
Customer Message
Privacy
米乐m6:Legal Statement
Compliance
EN
简体
EN
繁體
Home
About Henlius
米乐m6:Company Profile
米乐m6:Corporate Culture
Honor
米乐m6:Board of Directors
米乐m6:Management Team
米乐m6:Advisory Committee
Product
Marketed Products
Products in R&D
米乐m6:Clinical Trial
米乐m6:Science & Technology
米乐m6:R&D Result
Innovation Centre
Technology Platform
米乐m6:Quality Management
Manufacturing
米乐m6:Collaborations
Investor Relations
Information Disclosure
米乐m6:Listing Documents
米乐m6:Announcement & Circulars
米乐m6:Corporate Governance
米乐m6:Financial Reports
Stock Info
IR Calendar
米乐m6:Investor Presentation
米乐m6:Analyst Coverage
米乐m6:Contact Information
Media
米乐m6:Press Release
2022
2021
2020
2019
2018
2017
2016
2015
2014
Multi-media
Company
Event
Popular Science
米乐m6:Media Reports
Media Enquiry
Careers
Talent Philosophy
米乐m6:Staff Life
Training and Development
Job Opportunities
Contact Us
米乐m6:Contact Information
Customer Message
Privacy
米乐m6:Legal Statement
米乐m6:Compliance
Be the most trusted biotech company
Press Release
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Multi-media
Company
Popular Science
Highlights
Download
Media Reports
Media Enquiry
2020-12-17
NMPA Has Accepted The NDA of HLX01(Rituximab Injection) for the Treatment of Rheumatoid Arthritis
2020-12-07
Henlius Adalimumab Biosimilar 汉达远® Approved by NMPA
2020-11-20
Henlius Released Phase 3 Study Data of its Bevacizumab Biosimilar HLX04 at ESMO Asia 2020
2020-11-12
The IND Application of Henlius Daratumumab Biosimilar Accepted by NMPA
2020-11-09
First Patient Dosed in Phase 1 Clinical Trial of Henlius Denosumab Biosimilar HLX14
2020-11-06
Henlius ACE2-Fc Fusion Protein HLX71 Received IND Approval from US FDA
2020-10-29
The Results of the Phase 3 Study of Henlius’ Adalimumab Biosimilar HLX03 Presented on EADV 2020
2020-10-15
Henlius and Essex Enter into a Global Co-Development and Exclusive License Agreement, to Jointly Develop Bevacizumab to Treat Ophthalmic Diseases
2020-10-05
Investigational New Drug Application of Henlius SARS-CoV-2 Neutralizing Antibody HLX70 Approved by US FDA
1
2
3
...
5
var _hmt = _hmt || []; (function() { var hm = document.createElement("script"); hm.src = "https://hm.baidu.com/hm.js?90c4d9819bca8c9bf01e7898dd269864"; var s = document.getElementsByTagName("script")[0]; s.parentNode.insertBefore(hm, s); })(); !function(p){"use strict";!function(t){var s=window,e=document,i=p,c="".concat("https:"===e.location.protocol?"https://":"http://","sdk.51.la/js-sdk-pro.min.js"),n=e.createElement("script"),r=e.getElementsByTagName("script")[0];n.type="text/javascript",n.setAttribute("charset","UTF-8"),n.async=!0,n.src=c,n.id="LA_COLLECT",i.d=n;var o=function(){s.LA.ids.push(i)};s.LA?s.LA.ids&&o():(s.LA=p,s.LA.ids=[],o()),r.parentNode.insertBefore(n,r)}()}({id:"K9y7iMpaU8NS42Fm",ck:"K9y7iMpaU8NS42Fm"});
米乐m6登录 - m6平台 - 米乐m6
米乐m6 - 米乐m6登陆
米乐m6app下载
米乐m6平台 - 官方下载 - 米乐m6在线登录
一分赛车_米乐m6_一分赛车官网